Choroidal Neovascularization

Editor’s note: This is a developing news story. Please check back soon for updates.

KOLOA, Hawaii — Assessing fellow eye status, age and history of uveitis are helpful ways to determine which patients are most likely to benefit from treatment with FDA-approved drugs for geographic atrophy, according to a speaker.

BARCELONA, Spain — In the phase 2 ARCHER trial, ANX007, a novel C1q inhibitor with neuroprotective properties, showed consistent protection against loss of visual acuity in eyes with geographic atrophy.

Patients with neovascular age-related macular degeneration who experienced catastrophic vision loss after subretinal hemorrhage were linked to longer anti-VEGF treatment duration and shorter time from prior injection.

SEATTLE — In this Healio Video Perspective from the Retina World Congress, Andrew A. Moshfeghi, MD, MBA, discusses treating patients with age-related macular degeneration with concomitant geographic atrophy and choroidal neovascularization.

Initial study data indicate GEM103 can regulate complement activity in geographic atrophy secondary to dry age-related macular degeneration and has a tolerable safety profile, according to a press release.

The first patient has been dosed in a phase 2 trial investigating IBI302 in patients with choroidal neovascularization secondary to wet age-related macular degeneration, according to a press release from Innovent Biologics.

A 7-year-old girl presented to the pediatric ophthalmology clinic complaining of blurry vision in both eyes. She reported that her blurry vision started approximately a year ago and was worse at distance. She denied diplopia and any ocular pain. She has had mild headaches that do not change with position and have not been associated with any intracranial noises. She denied any fevers, chills and night sweats. She was born full-term and had an otherwise unremarkable medical history. She did not have any personal ocular history nor family ocular history.

Persistent subretinal fluid, or SRF, in the course of anti-VEGF treatment may operate as a compensatory mechanism that maintains the function of the degenerating macula and prevents progression to atrophy, according to one presenter at the virtual Association for Research in Vision and Ophthalmology meeting.

The Bascom Palmer Angiogenesis meeting took place on Feb. 8, covering disease pathogenesis and emerging treatment options for various retinal conditions. The presentations highlighted how some of the newest imaging modalities are helping us understand the natural course of disease and new mechanisms of action being evaluated as alternatives to our current treatments. Below is just a mere highlight of many excellent presentations at the meeting.